Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine

Completed · Phase 4 · Has a placebo group

Conditions studied: Migraine

In brief

The primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity.

Key facts

Study ID
NCT04252742
Run by
Amgen
People needed
512
Starts
2020-09-15
Expected to finish
2023-10-26
Last updated by the study team
2026-03-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.